Fitish RX’s standard weight-management menu includes compounded semaglutide with vitamin B6 at $219 per monthly supply and compounded tirzepatide injection at $339. It also lists an oral tirzepatide product at $339 and a separate fixed microdose program. These should be treated as distinct product and care questions, even when the ingredient name overlaps. [Source]
This review focuses on how the standard offers are described, what the package includes and what the public policies leave unresolved. We did not purchase treatment, test an oral formulation, verify an individual prescription or compare patient outcomes. A product’s advertised mechanism and a provider’s service description do not establish that two formulations perform the same way.
The published standard-program prices
The semaglutide page describes a monthly supply of compounded semaglutide with B6 for $219, including the provider consultation, medication if approved and shipping. The tirzepatide injection page gives the same package description at $339. Both say there is no separate consultation or membership fee. [Source]
The rendered semaglutide cards display $195 per month on a three-month bundle and $175 on six months. Tirzepatide injection cards display $305 and $270 for those terms; the oral product shows the same longer-plan equivalents. The pages also advertise 10% and 20% bundle savings, applied during intake. We did not verify the full selected charge, payment schedule or renewal amount. Use the actual written quote rather than calculating a purchase solely from the discount label. [Source]
The standard pages refer to a monthly supply and monthly shipping cadence. Ask for the actual number of days supplied, shipment schedule and recurring charge date. The plan should specify those details rather than leaving the reader to assume that every monthly label represents the same quantity or billing interval. [Source]
An oral tablet is a separate formulation question
The oral tirzepatide page advertises a $339 monthly supply with consultation, prescribed medication and shipping. It describes a compounded oral tablet and acknowledges that it is not an FDA-approved product. This is not the same route or formulation as the approved tirzepatide injections discussed in branded trials. [Source]
The page uses dual-receptor activity to explain the ingredient. Mechanism alone does not establish how much of an oral preparation is absorbed, how its clinical effects compare with an injection or whether it delivers the same benefit-risk profile. We did not identify a product-specific comparative clinical study in the reviewed materials. [Source]
Ask the prescriber for the reason to choose the proposed preparation, the evidence supporting that route and the alternatives. This review does not turn the oral marketing description into a recommendation or supply directions for taking it.
Standard weight management and microdosing are different offers
The standard product pages also list semaglutide microdosing at $179 and tirzepatide microdosing at $269 per monthly supply. [Semaglutide offer] [Tirzepatide offer] The FAQ distinguishes these fixed low-dose wellness and cosmetic offerings from the standard weight-management programs, which it describes as adjusted by a provider over time. [Source]
Descriptions such as gentler or mindful are marketing language, not proof of reduced risk or an approved cosmetic indication. The existence of two price categories does not determine which treatment is appropriate. That requires an individual clinician’s assessment, including whether medication is warranted at all. [Source]
For every proposed compounded preparation, FDA’s approval distinction remains relevant: these drugs do not receive its premarket review for safety, effectiveness and quality. An approved medicine’s trial findings cannot simply be transferred to a different route, combination or regimen. [Source]
Who supplies care and where it is available
The general terms identify the website operator as FITISH. The reviewed public material describes licensed providers and licensed compounding pharmacies but did not establish the actual medical group, prescribing clinician or dispensing pharmacy for a particular order. Obtain those names before treating a brand-level description as a verified care arrangement. [Source]
The service-area page says care is available in all 50 states and Washington, DC, subject to clinical suitability, medication restrictions and licensure. It describes online-questionnaire care in 44 states and live consultation in DC, Kansas, Louisiana, Mississippi, New Mexico, Rhode Island and West Virginia. Those are the company’s operating descriptions, not an independent conclusion about state law or every patient’s eligibility. [Source]
Fitish advertises regular check-ins, progress tracking and direct portal messaging, and describes cash-pay care without insurance billing. We did not measure response times, fulfillment or continuity between clinicians. Ask how an urgent clinical concern differs from an ordinary refill or account message. [Source]
The public return policy does not answer every exit question
The Return & Exchange Policy says prescription medications cannot be returned, exchanged or resold once shipped. For damage, defects or an incorrect item it asks customers to contact the care team promptly; for an undeliverable package it describes arranging a corrected reshipment. It does not state a universal monetary refund calculation for those situations. [Source]
The reviewed general terms and return page do not resolve the selected plan’s renewal cutoff, a cancellation before shipment, an assessment denial or unused portions of a three- or six-month bundle. This is a limit of the reviewed public documentation, not a claim that no additional agreement exists during intake. [Source]
Request the plan-specific agreement before payment and save the cancellation instructions. Ask separately about stopping a future renewal and recovering an already charged amount. The prescriber should also explain how care continues or transfers if the commercial plan ends.
Keep the comparison tied to the actual preparation
Fitish’s public pages make its standard injection prices and included services visible. The remaining decision needs the exact pharmacy, formulation, bundle terms and evidence for the proposed route. A product menu is a starting point for those questions rather than proof that its options are interchangeable.
Read the product identity explainer, then compare the Ondra Health review for a different plan and pharmacy structure. Neither a lower price nor an additional receptor target establishes which care arrangement is clinically best for a particular person.
Follow the evidence
New provider sources checked October 15, 2026. Earlier material retains its original source history. Trial abstracts support only the limited summaries identified in the article. Provider pages document advertised offers.
- Fitish RX: Compounded semaglutide with B6Provider public information; checked October 15, 2026
- Fitish RX: Compounded tirzepatide injectionProvider public information; checked October 15, 2026
- Fitish RX: Oral tirzepatide tabletsProvider public information; checked October 15, 2026
- Fitish RX: Return and exchange policyProvider public information; checked October 15, 2026
- Fitish RX: State service descriptionsProvider public information; checked October 15, 2026
- Fitish RX: Terms and conditionsProvider public information; checked October 15, 2026
- Fitish RX: Care and program FAQProvider public information; checked October 15, 2026
- FDA — concerns with unapproved GLP-1 drugsRegulator guidance